Research Collaboration And License Agreement Sample Contracts

Arvinas Holding Company, Llc – Research Collaboration and License Agreement (September 14th, 2018)

This Agreement (this Agreement) is effective as of December 22, 2017 (the Effective Date), and is entered into by and between Arvinas, Inc., a corporation organized and existing under the laws of Delaware, located at 5 Science Park, 395 Winchester Ave., New Haven, CT 06511 (Arvinas) and Pfizer Inc., a corporation organized and existing under the laws of Delaware, located at 235 East 42nd Street, New York, NY 10017 (Pfizer).

Allogene Therapeutics, Inc. – Research Collaboration and License Agreement by and Between Pfizer Inc. And Cellectis Sa June 17, 2014 (September 14th, 2018)
Arvinas Holding Company, Llc – Research Collaboration and License Agreement (August 30th, 2018)

This Agreement (this Agreement) is effective as of December 22, 2017 (the Effective Date), and is entered into by and between Arvinas, Inc., a corporation organized and existing under the laws of Delaware, located at 5 Science Park, 395 Winchester Ave., New Haven, CT 06511 (Arvinas) and Pfizer Inc., a corporation organized and existing under the laws of Delaware, located at 235 East 42nd Street, New York, NY 10017 (Pfizer).

Affimed Therapeutics B.V. – Confidential Research Collaboration and License Agreement Between Affimed Gmbh and Genentech, Inc. As of August 24, 2018 (August 27th, 2018)

This Research Collaboration and License Agreement ("Agreement") is made and entered into as of August 24, 2018 ("Signing Date"), by and between Affimed, GmbH, having its principal place of business at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany ("AFMD"), and Genentech, Inc., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 ("GNE"). AFMD and GNE are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Amendment No. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT Between SAVARA INC. And PARI Pharma GmbH (August 9th, 2018)

This first amendment ("Amendment No. 1") to the Research Collaboration and License Agreement, effective as of 7th day of November 2014, between PARI Pharma GmbH, Moosstrasse 3, D-82319 Starnberg, Germany ("PARI") and Serendex Pharmaceuticals A/S, Slotsmarken 17, 2.tv., DK-2970 Horsholm, Denmark ("Serendex") (the "Agreement"), is made effective as of May 23rd, 2018 ("Amendment No. 1 Effective Date") by and between PARI and Savara Inc. with a principal place of business at 6836 Bee Cave Road, Building 3, Suite 200, Austin, TX, 78746, United States of America ("Savara"). PARI and Savara shall be referred to each as a "Party" and collectively as the "Parties".

Arvinas Holding Company, Llc – Research Collaboration and License Agreement (June 22nd, 2018)

This Agreement (this Agreement) is effective as of December 22, 2017 (the Effective Date), and is entered into by and between Arvinas, Inc., a corporation organized and existing under the laws of Delaware, located at 5 Science Park, 395 Winchester Ave., New Haven, CT 06511 (Arvinas) and Pfizer Inc., a corporation organized and existing under the laws of Delaware, located at 235 East 42nd Street, New York, NY 10017 (Pfizer).

Alcobra Ltd. – Research Collaboration and License Agreement (May 14th, 2018)

This Research Collaboration and License Agreement (this "Agreement") is entered into as of October 26, 2015 (the "Effective Date") by and between Ultragenyx Pharmaceutical Inc., a Delaware corporation having an address at 60 Leveroni Court, Novato, CA 94949 ("Ultragenyx"), and Arcturus Therapeutics, Inc. a Delaware corporation having an address at 10628 Science Center Drive, Suite 200, San Diego, CA 92121 ("Arcturus"). Arcturus and Ultragenyx are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Alcobra Ltd. – RESEARCH COLLABORATION AND LICENSE AGREEMENT Between Arcturus Therapeutics, Inc. And Janssen Pharmaceuticals, Inc. (May 14th, 2018)

This research collaboration and license Agreement (this "Agreement") is dated October 18, 2017 (the "Effective Date"), and is between Arcturus Therapeutics, Inc., a Delaware corporation ("Arcturus"), and Janssen Pharmaceuticals, Inc., a Delaware corporation ("JPI"). Each of Arcturus and JPI may be referred to herein individually as a "Party" and collectively as the "Parties".

Research Collaboration and License Agreement (April 24th, 2018)

This Research Collaboration and License Agreement (the Agreement) is entered into as of December 28, 2017 (the Effective Date), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (Pfizer) and Sangamo Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 501 Canal Blvd., Richmond, CA 94804 (Sangamo). Pfizer and Sangamo may each be referred to herein individually as a Party and collectively as the Parties.

Research Collaboration and License Agreement (March 1st, 2018)

This Research Collaboration and License Agreement (the "Agreement") is entered into as of December 28, 2017 (the "Effective Date"), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 ("Pfizer") and Sangamo Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 501 Canal Blvd., Richmond, CA 94804 ("Sangamo"). Pfizer and Sangamo may each be referred to herein individually as a "Party" and collectively as the "Parties."

Marika – CONFIDENTIAL TREATMENT REQUESTED AMENDMENT 1 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT by and Between (August 11th, 2017)

with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (Roche US; Roche Basel and Roche US together referred to as Roche)

Execution Copy RESEARCH COLLABORATION AND LICENSE AGREEMENT (February 10th, 2017)

This Research Collaboration and License Agreement (this Agreement) is made effective as of 7th day of November 2014, (the Effective Date) by and between Serendex Pharmaceuticals A/S, Slotsmarken 17, 2.tv., DK-2970 Horsholm, Denmark (Serendex), and PARI Pharma GmbH, Moosstrabe 3, D-82319 Starnberg, Germany (PARI). Each of Serendex and PARI is a Party hereto and collectively they are the Parties.

AC Immune SA – Research Collaboration and License Agreement (September 13th, 2016)

This Research Collaboration and License Agreement (Agreement) is made and entered into as of the 15th day of June 2012 (the Effective Date) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (GNE) and F. Hoffmann-La Roche Ltd, a Swiss corporation with its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (Roche) (GNE and Roche, collectively, Genentech). ACI and Genentech are each referred to herein individually as a Party and collectively as the Parties.

Kite Pharma, Inc. – Research Collaboration and License Agreement (August 8th, 2016)

This RESEARCH COLLABORATION AND LICENSE AGREEMENT (the "Agreement"), effective as of June 1, 2016 (the "Effective Date"), is made by and between CELL DESIGN LABS, INC., a Delaware corporation with its principal place of business at 4165 Canyon Road, Lafayette, CA 94549 ("CDL"), and KITE PHARMA, INC., a Delaware corporation with registered address at 2225 Colorado Avenue, Santa Monica, CA 90404 ("Kite"). CDL and Kite are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Kite Pharma, Inc. – RESEARCH COLLABORATION AND LICENSE AGREEMENT by and Between AMGEN INC. And KITE PHARMA, INC. Dated as of December 31, 2014 (August 8th, 2016)

This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this "Agreement") is entered into as of December 31, 2014 (the "Signing Date") by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 ("Amgen"), and KITE PHARMA, INC., a Delaware corporation having an address at 2225 Colorado Avenue, Santa Monica, California 90404 ("Kite"). Kite and Amgen are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Mount TAM Biotechnologies, Inc. – Amendment No. 3 to Research Collaboration and License Agreement (July 22nd, 2016)

THIS AMENDMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT (herein referred to as "Amendment No. 3") is made and entered into as of July 19, 2016 (the "Effective Date"), by and between Mount Tam Biotechnologies, Inc."), a Nevada corporation, (herein referred to as "TAM"), and The Buck Institute for Research on Aging, an independent non-profit research organization organized under the laws of California ("Buck"), each herein referred to individually as "Party" and collectively as "Parties."

Marika – CONFIDENTIAL TREATMENT REQUESTED Research Collaboration and License Agreement (July 20th, 2016)

with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (Roche US; Roche Basel and Roche US together referred to as Roche)

AC Immune SA – Research Collaboration and License Agreement (May 31st, 2016)

This Research Collaboration and License Agreement (Agreement) is made and entered into as of the 6th day of November, 2006 (the Effective Date) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (Genentech). ACI and Genentech are each referred to herein individually as a Party and collectively as the Parties.

AC Immune SA – Research Collaboration and License Agreement (May 31st, 2016)

This Research Collaboration and License Agreement (Agreement) is made and entered into as of the 15th day of June 2012 (the Effective Date) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (GNE) and F. Hoffmann-La Roche Ltd, a Swiss corporation with its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (Roche) (GNE and Roche, collectively, Genentech). ACI and Genentech are each referred to herein individually as a Party and collectively as the Parties.

AC Immune SA – Confidential Treatment Requested Under Rule 406 Under the Securities Act of 1933, as Amended. [*****] Indicates Omitted Material That Is the Subject of a Confidential Treatment Request Filed Separately With the Commission. The Omitted Material Has Been Filed Separately With the Commission. Amendment to Research Collaboration and License Agreement (May 31st, 2016)

This Amendment to the Research Collaboration and License Agreement dated November 6, 2006 (the Amendment), is made by and between the Parties: AC Immune SA, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (Genentech).

Marika – CONFIDENTIAL TREATMENT REQUESTED Research Collaboration and License Agreement (April 29th, 2016)

with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (Roche US; Roche Basel and Roche US together referred to as Roche)

Marika – CONFIDENTIAL TREATMENT REQUESTED Research Collaboration and License Agreement (March 23rd, 2016)

with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (Roche US; Roche Basel and Roche US together referred to as Roche)

Respiratory Diseases Research Collaboration and License Agreement (March 11th, 2016)

This Amendment No. 3 to the Respiratory Diseases Research Collaboration and License Agreement, effective as of January 26, 2016 (this "Amendment No. 3"), is made by and between Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, England ("GSK"), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080, USA ("FivePrime").

Amendment No. 1 to the Research Collaboration and License Agreement (March 11th, 2016)

This Amendment No. 1 to the Research Collaboration and License Agreement (this "Amendment"), effective January 21, 2016 (the "Amendment Effective Date"), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation ("FivePrime"), and Bristol-Myers Squibb Company, a Delaware corporation ("BMS").

Amendment No. 2 to the Research Collaboration and License Agreement (March 11th, 2016)

This Amendment No. 2 to the Research Collaboration and License Agreement (this "Amendment"), effective as of July 27, 2015 (the "Amendment Effective Date"), is made by and between UCB Pharma S.A., a Belgium corporation ("UCB"), and Five Prime Therapeutics, Inc., a Delaware corporation ("FivePrime").

Amendment No. 1 to Research Collaboration and License Agreement (March 9th, 2016)

This Amendment No. 1 to Research Collaboration and License Agreement (this "Amendment") is made as of this 10th day of November 2015 (the "Effective Date"), by and between GenVec, Inc., a Delaware corporation ("GenVec") and Novartis Institutes for Biomedical Research, Inc., a Delaware corporation ("Novartis"), and amends that Research Collaboration and License Agreement dated January 13, 2010 (the "License Agreement"), by and between Novartis and GenVec. Capitalized terms used in this Amendment without definition shall have the meanings given those terms in License Agreement.

AC Immune SA – Research Collaboration and License Agreement (November 24th, 2015)

This Research Collaboration and License Agreement (Agreement) is made and entered into as of the 6th day of November, 2006 (the Effective Date) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (Genentech). ACI and Genentech are each referred to herein individually as a Party and collectively as the Parties.

AC Immune SA – Research Collaboration and License Agreement (November 24th, 2015)

This Research Collaboration and License Agreement (Agreement) is made and entered into as of the 15th day of June 2012 (the Effective Date) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (GNE) and F. Hoffmann-La Roche Ltd, a Swiss corporation with its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (Roche) (GNE and Roche, collectively, Genentech). ACI and Genentech are each referred to herein individually as a Party and collectively as the Parties.

Research Collaboration and License Agreement (November 5th, 2015)

This Research Collaboration and License Agreement (this "Agreement"), effective as of July 13, 2015 (the "Effective Date"), is entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation ("FivePrime"), and INBRX 110 LP, a Delaware limited partnership ("INBRX"). FivePrime and INBRX are each referred to individually as a "Party" and collectively as the "Parties."

AC Immune SA – Research Collaboration and License Agreement (September 25th, 2015)

This Research Collaboration and License Agreement (Agreement) is made and entered into as of the 6th day of November, 2006 (the Effective Date) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (Genentech). ACI and Genentech are each referred to herein individually as a Party and collectively as the Parties.

AC Immune SA – Confidential Treatment Requested Under Rule 406 Under the Securities Act of 1933, as Amended. [*****] Indicates Omitted Material That Is the Subject of a Confidential Treatment Request Filed Separately With the Commission. The Omitted Material Has Been Filed Separately With the Commission. Amendment to Research Collaboration and License Agreement (September 25th, 2015)

This Amendment to the Research Collaboration and License Agreement dated November 6, 2006 (the Amendment), is made by and between the Parties: AC Immune SA, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (Genentech).

AC Immune SA – Research Collaboration and License Agreement (September 25th, 2015)

This Research Collaboration and License Agreement (Agreement) is made and entered into as of the 15th day of June 2012 (the Effective Date) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (ACI) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (GNE) and F. Hoffmann-La Roche Ltd, a Swiss corporation with its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (Roche) (GNE and Roche, collectively, Genentech). ACI and Genentech are each referred to herein individually as a Party and collectively as the Parties.

Amendment to the Research Collaboration and License Agreement (May 8th, 2015)

This Amendment to the Research Collaboration and License Agreement (this Amendment) is entered into as of February 27, 2015, by and between Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the laws of Delaware, with its principal place of business at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, and Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, with its principal place of business at 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142.

Kite Pharma, Inc. – RESEARCH COLLABORATION AND LICENSE AGREEMENT by and Between AMGEN INC. And KITE PHARMA, INC. Dated as of December 31, 2014 (March 26th, 2015)

This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this "Agreement") is entered into as of December 31, 2014 (the "Signing Date") by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 ("Amgen"), and KITE PHARMA, INC., a Delaware corporation having an address at 2225 Colorado Avenue, Santa Monica, California 90404 ("Kite"). Kite and Amgen are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Cellectis S.A. – Research Collaboration and License Agreement by and Between Pfizer Inc. And Cellectis Sa June 17, 2014 (March 12th, 2015)

This Research Collaboration and License Agreement (the Agreement) is entered into as of June 17, 2014 (the Effective Date), by and among Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (Pfizer) and Cellectis SA, a corporation organized and existing under the laws of France and having a place of business at 8 rue de la Croix Jarry, 75013 Paris, France (Cellectis). Pfizer and Cellectis may each be referred to herein individually as a Party and collectively as the Parties.